Docoh
Loading...

AMRN Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Company profile

Ticker
AMRN
Exchange
CEO
John Thero
Employees
Incorporated
Location
Fiscal year end
Former names
AMARIN PHARMACEUTICALS PLC, ETHICAL HOLDINGS PLC
SEC CIK

AMRN stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

25 Feb 21
17 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Amarin earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 186.96M 186.96M 186.96M 186.96M 186.96M 186.96M
Cash burn (monthly) 6.75M 38.14M (positive/no burn) 1.58M 12.77M 1.81M
Cash used (since last report) 24.12M 136.3M n/a 5.65M 45.66M 6.48M
Cash remaining 162.85M 50.67M n/a 181.32M 141.31M 180.49M
Runway (months of cash) 24.1 1.3 n/a 114.8 11.1 99.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Mar 21 Joseph T Kennedy Ordinary Shares Payment of exercise Dispose F No No 6.37 3,803 24.23K 304,192
31 Mar 21 Joseph T Kennedy Ordinary Shares Option exercise Aquire M No No 0 3,610 0 307,995
31 Mar 21 Joseph T Kennedy Ordinary Shares Option exercise Aquire M No No 0 1,805 0 304,385
31 Mar 21 Joseph T Kennedy Ordinary Shares Option exercise Aquire M No No 0 1,805 0 302,580
31 Mar 21 Joseph T Kennedy RSU Ordinary Shares Option exercise Dispose M No No 0 3,610 0 18,050
31 Mar 21 Joseph T Kennedy RSU Ordinary Shares Option exercise Dispose M No No 0 1,805 0 9,025
31 Mar 21 Joseph T Kennedy RSU Ordinary Shares Option exercise Dispose M No No 0 1,805 0 9,025
31 Mar 21 Steven B Ketchum Ordinary Shares Payment of exercise Dispose F No No 6.37 3,128 19.93K 440,230
31 Mar 21 Steven B Ketchum Ordinary Shares Option exercise Aquire M No No 0 3,056 0 443,358
31 Mar 21 Steven B Ketchum Ordinary Shares Option exercise Aquire M No No 0 1,528 0 440,302

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

37.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 242 259 -6.6%
Opened positions 43 38 +13.2%
Closed positions 60 59 +1.7%
Increased positions 42 82 -48.8%
Reduced positions 86 65 +32.3%
13F shares
Current Prev Q Change
Total value 1.08B 664.15M +62.6%
Total shares 148.39M 147.16M +0.8%
Total puts 5.7M 6.87M -16.9%
Total calls 7.21M 6.11M +18.0%
Total put/call ratio 0.8 1.1 -29.6%
Largest owners
Shares Value Change
Baker Bros. Advisors 27.99M $136.88M -12.6%
Eversept Partners 15.94M $77.97M +49.7%
BVF 10.76M $52.62M +878.3%
Boxer Capital 6M $29.34M -14.3%
Avoro Capital Advisors 6M $29.34M 0.0%
MS Morgan Stanley 5.98M $29.22M +198.3%
Grosvenor Holdings, L.L.C. 5.89M $28.8M +8.7%
SCP Investment 5.5M $26.9M +120.0%
Clearbridge Advisors 4.63M $22.62M +56.4%
Rock Springs Capital Management 4.2M $20.51M -3.6%
Largest transactions
Shares Bought/sold Change
BVF 10.76M +9.66M +878.3%
Eversept Partners 15.94M +5.29M +49.7%
Artisan Partners Limited Partnership 0 -5.19M EXIT
Avidity Partners Management 0 -4.51M EXIT
Baker Bros. Advisors 27.99M -4.03M -12.6%
MS Morgan Stanley 5.98M +3.97M +198.3%
D. E. Shaw & Co. 3.85M -3M -43.8%
SCP Investment 5.5M +3M +120.0%
First Light Asset Management 0 -2.24M EXIT
DG Capital Management 2.22M +2.22M NEW
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: affiliate, ahead, Aid, AMPLIFY, angiographic, answer, Arabia, argued, attitude, Bahrain, beneficiary, Benjamin, Biden, biosimilar, boxed, Brigham, burdensome, CABG, CADTH, CAL, calcium, capita, career, CD, certiorari, checking, CHMP, CID, clear, cohesively, commenrcialization, composed, consequentially, contact, contacting, convince, coordinated, coordination, DEF, Defintiion, dense, destabilized, DH, diagnosed, diligently, discouraged, distancing, distracting, divergence, doctor, DOJ, drop, dying, EC, economy, Edding, elderly, emia, emphasize, emphasizing, ensued, era, excellence, Fake, fewer, fibrofatty, forthcoming, Franc, FY, FYs, gated, gender, geographically, globe, Grafenauweg, grafting, hall, hard, Harvard, height, heightened, hereinafter, hereto, honor, honoring, hope, hourly, hypercholesterol, IA, IIb, impeding, inexpensive, infected, infection, inflow, influenza, Inilne, input, Inspector, intelligence, Irelnad, irrespective, ischemic, Italy, Justice, justified, Lable, LAP, lenient, leverage, Liaison, Linkbase, LYPDISO, manmade, MDCT, medium, metformin, MFN, modest, morale, multidetector, multifactorial, multivariable, NMPA, Nordic, OIG, OMEMI, OPML, optimistic, orientation, overly, overturned, pandemic, paused, PCI, PD, Peterson, postulated, precautionary, predominately, prostate, race, reaccelerate, reactive, receent, rehearin, reinforcement, reinstitution, religion, remote, remotely, renumeration, reportedly, reprioritization, respitory, restraining, resume, resumed, resumption, retention, rewarding, rightsized, Saudi, saving, scan, Schema, School, score, Secretary, sequester, sexual, SHTG, signature, singly, slightly, speaker, speaking, spike, steadily, strained, summer, surgical, surrendered, Switzerland, symptom, symptomatic, talent, Taxanomy, Taxonmy, TCT, tension, text, timeframe, tissue, tolderated, tomography, town, traditional, Transcatheter, treble, TRIAGE, undergone, underwent, unrealized, unscheduled, upholding, uptake, usage, vaccinated, VASEPA, vast, VAZKEPA, viral, widespread, witnessed, workforce, worsened, worsensed, worst, writ, wrong, Zug
Removed: abandon, abnormally, Acasti, acceleration, aggressively, amounted, attractive, BCF, bifurcation, bond, bridge, cancelled, CaPre, classification, concomitantly, contingency, conversion, Covenant, dedicate, Deed, default, dismissal, Docket, domain, encumber, entirety, existed, expensing, feasibility, formed, generation, host, house, inclusive, initiating, injunctive, instituted, issuable, krill, largely, leased, mandatorily, marked, maturing, Medica, membrane, memorandum, morbidity, Neptune, Nisshin, notified, notifying, partnering, perfected, pertaining, plasticity, prefer, prepay, preserving, pretrial, privately, provisional, PTAB, ran, recalculated, reclassification, reclassified, refinement, remedy, representation, rescinding, restate, send, shortfall, speculative, subscribed, Subtopic, Tariff, training, transition, unchanged, uncured, USITC, vulnerability, warrant, wholly

Patents

GRANT
Utility
Compositions and methods for lowering levels of high-sensitivity C-reactive protein (hs-CRP) in a subject
13 Apr 21
The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
GRANT
Utility
Methods of reducing apolipoprotein c-III
13 Apr 21
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
APP
Utility
Methods of Treating Mixed Dyslipidemia
8 Apr 21
The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
APP
Utility
Methods of Treating Mixed Dyslipidemia
8 Apr 21
The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
APP
Utility
Methods of Reducing the Risk of Cardiovascular Events In a Subject
8 Apr 21
In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.